Join the Renal Cell Carcinoma group to help and get support from people like you.
Renal Cell Carcinoma News
Related terms: Adenocarcinoma of renal cells, Cancer, Hypernephroma, Cancer, Kidney, Cancer, Renal, Cancer, Renal Cell Carcinoma, Hypernephroma, Kidney Cancer, Renal Cancer
Tivozanib Has Efficacy in Advanced Renal Cell Carcinoma Post-ICI Therapy
FRIDAY, Sept. 20, 2024 – For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, including one immune checkpoint inhibitor (ICI),...
Combo Treatment Doubles Survival for Patients With Advanced Kidney Cancer
TUESDAY, Sept. 17, 2024 – A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer. Researchers at Roswell Park Comprehensive Cancer...
Belzutifan Improves Progression-Free Survival in Advanced Renal Cell Cancer
FRIDAY, Aug. 23, 2024 – Belzutifan, a hypoxia-inducible factor 2α (HIF-2α) inhibitor, improves progression-free survival and objective responses over everolimus among patients with advanced c...
Most Cancer Treatments Near End of Life Are Useless: Study
FRIDAY, May 17, 2024 – Cutting-edge cancer treatments are essentially useless for patients barely clinging to life, a new study shows. Chemotherapies, immunotherapies, targeted therapies and hormone...
GWAS Identifies 108 Independent Risk Loci for Kidney Cancer
THURSDAY, May 2, 2024 – A genome-wide association study meta-analysis, published online April 26 in Nature Genetics, has identified 63 susceptibility regions containing 108 independent risk loci for...
Improvement Seen in Survival With Adjuvant Pembrolizumab in Kidney Cancer
THURSDAY, April 18, 2024 – For patients with clear-cell renal cell carcinoma, adjuvant pembrolizumab is associated with a significant and clinically meaningful improvement in overall survival,...
Pembrolizumab Shows Survival Benefit for Patients With Renal Cancer
WEDNESDAY, Jan. 31, 2024 – For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of...
Injected Opdivo for Kidney Cancer Works Equally Well as IV Form: Study
TUESDAY, Jan. 30, 2024 – Opdivo, one of the new generation of immunotherapy cancer treatments, appears to help kidney cancer patients equally well when given as a quick injection versus the current...
FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
Survival Improved With Everolimus in High-Risk Clear Cell Renal Cancer
MONDAY, Oct. 23, 2023 – For patients with clear cell renal cell carcinoma (RCC) at very high risk for recurrence, adjuvant everolimus is associated with significantly improved recurrence-free...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021 Keytruda Plus Lenvima Is Now Approved for Two Types of Cancer, Including Advanced RCC Based on Phase 3 CLEAR/KEYNOTE-581 Trial, Keytruda Plus Lenvima Significantly Reduced Risk of...
FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
BOSTON--(BUSINESS WIRE) March 10, 2021 – AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved Fotivda (tivozanib) for the treatment of adults...
FDA Approves Opdivo (nivolumab) in Combination with Cabometyx (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) January 22, 2021-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every...